Annaliesa Anderson | SVP & Chief Vaccines Officer
Pfizer

Dr. Annaliesa Anderson is Senior Vice President and Chief Vaccines Officer at Pfizer, where she leads the company's global vaccines research, development, and medical affairs organization. She oversees an end-to-end portfolio spanning discovery through post-licensure, with a focus on developing innovative vaccines to help prevent infectious diseases worldwide. With more than 30 years of experience in the biopharmaceutical industry, Dr. Anderson has played a key role in the development of numerous vaccines, including vaccines for human papillomavirus (HPV), pneumococcal disease, meningococcal disease, COVID-19, and respiratory syncytial virus (RSV). During the COVID-19 pandemic, she also co-led the development of a licensed oral antiviral treatment for COVID-19. Dr. Anderson earned her PhD in Biological Sciences from the University of Warwick in the United Kingdom and received an honorary Doctor of Science degree from Manchester Metropolitan University. She has authored more than 170 peer-reviewed publications and book chapters and holds an extensive patent portfolio in vaccines and anti-infective research and development. A recognized scientific leader, Dr. Anderson has received awards for her contributions to mentoring and advancing diversity in science. In 2024, she was named among the Top 20 Women in Biopharma by Endpoints News. She is an elected Fellow of the American Academy of Microbiology, the American Association for the Advancement of Science, the Infectious Diseases Society of America, and the Academy of Medical Sciences. She is also a Fellow of the Royal Society of Medicine and serves on multiple scientific and policy advisory boards. Dr. Anderson is passionate about scientific education, mentorship, and developing the next generation of scientists. Her career has been dedicated to advancing innovations that improve public health and help protect people from infectious diseases around the world.